Generic Dabrafenib Capsules 50mg & 75mg — BRAF Inhibitor for Melanoma & Lung Cancer

Generic Name: Dabrafenib
Trade Name: Dabradx
Available Strengths: 50 mg | 75 mg capsules
Drug Class: BRAF Kinase Inhibitor
Manufacture: Bigbear Pharmaceutical (lao) Co. Ltd
Shipping: Worldwide — USA, UK, Canada, Australia, India & more

⚠️ Prescription Required. Dabrafenib is a prescription-only cancer medicine. Always take this medication under the supervision of a qualified oncologist. This page is for informational and ordering purposes only.

What Is Generic Dabrafenib?

If your oncologist has prescribed dabrafenib, you may have encountered the brand name Tafinlar — and seen its price tag. Generic dabrafenib contains the exact same active ingredient at the same strength and works the same way in the body, but at a fraction of the cost. At 100Meds, we source generic dabrafenib from WHO-GMP certified manufacturers so that patients worldwide can access this treatment without financial hardship getting in the way.

Dabrafenib is a targeted cancer therapy — not traditional chemotherapy. It works precisely on a specific genetic mutation in cancer cells rather than attacking all fast-dividing cells in the body. That distinction matters both for how it works and for how patients generally tolerate it compared to conventional chemo.

What Is Dabrafenib Used For?

Dabrafenib targets cancers that carry a specific mutation in a gene called BRAF. About half of all melanomas and a significant proportion of non-small cell lung cancers carry this BRAF V600 mutation. Before starting dabrafenib, your doctor will test your tumor for this mutation — the drug is only effective when the mutation is present.

FDA-approved indications include:

• Unresectable or metastatic melanoma with BRAF V600E or V600K mutation (as a single agent or in combination with trametinib)
• Metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation (in combination with trametinib)
• Locally advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation, in patients with no satisfactory locoregional treatment options (in combination with trametinib)

Important: Dabrafenib is not effective in cancers that do not carry the BRAF V600 mutation. Your doctor must confirm your tumor’s mutation status before prescribing this medicine.

How Does Dabrafenib Work? (Simple Explanation)

Think of cancer cells as cars with a stuck accelerator — they keep growing and dividing even when they shouldn’t. In BRAF-mutated cancers, a protein called BRAF V600 acts as that stuck accelerator, constantly telling cells to multiply out of control.

Dabrafenib is a BRAF kinase inhibitor — it works like a roadblock that gets in the way of this faulty BRAF signal. By blocking the mutated BRAF protein, dabrafenib slows or stops cancer cell growth.

When dabrafenib is taken alongside trametinib (a MEK inhibitor), both drugs block the same cancer pathway at two different points simultaneously. Clinical studies have shown this combination is significantly more effective than either drug used alone, and it also reduces the risk of certain skin-related side effects that can occur with BRAF inhibitors used alone.

Dabrafenib Dosage Information

Dabrafenib comes in 50 mg and 75 mg capsules. Your doctor will prescribe the correct dose based on your condition and whether you are taking it alone or in combination.

How to take dabrafenib:

• Take on an empty stomach — at least 1 hour before or 2 hours after a meal
• Swallow the capsule whole — do not crush, open, or chew
• Take doses approximately 12 hours apart
• If you miss a dose, skip it if there are less than 6 hours until your next scheduled dose
• Do not eat grapefruit or take grapefruit juice while on this medication — it can interfere with how your body processes the drug

Never adjust or stop your dose without talking to your oncologist first. Dose reductions for side effects should only be done under medical supervision.

Dabrafenib Side Effects — What Patients Should Know

Like all medicines, dabrafenib can cause side effects. Most patients tolerate it reasonably well, but there are some important things to watch for. The list below covers the most common and the most serious ones.

Common side effects (may affect more than 1 in 10 patients):

• Fever (pyrexia) — one of the most frequent side effects, especially in the first few months. Can be managed with dose holds and supportive care. Tell your doctor promptly if your temperature rises above 38°C/100.4°F.
• Skin thickening (hyperkeratosis) and skin rash
• Headache and joint pain (arthralgia)
• Hair loss (alopecia)
• Fatigue
• Nausea

Serious side effects — seek immediate medical attention:

• New skin growths — dabrafenib can trigger new skin cancers (cutaneous squamous cell carcinoma). Your doctor will check your skin regularly.
• Bleeding — unusual bruising or unexplained bleeding anywhere in the body
• Eye problems — blurred vision, eye pain, or changes in vision (uveitis has been reported)
• Heart problems — shortness of breath, unusual fatigue, swollen ankles; dabrafenib can affect heart function (QTc prolongation) in some patients
• Low sodium levels (hyponatremia) — dizziness, confusion, muscle cramps

This is not a complete list of side effects. Read the full patient information leaflet provided with your medication, and discuss any concerns with your oncologist or pharmacist.

Important Warnings & Precautions

Before starting dabrafenib, tell your doctor if you:

• Have or have had any heart problems
• Have glucose-6-phosphate dehydrogenase (G6PD) deficiency — dabrafenib contains a lactose component and can cause haemolytic anaemia in G6PD-deficient patients
• Have diabetes — dabrafenib can cause high blood sugar (hyperglycemia)
• Are pregnant, planning to become pregnant, or breastfeeding — dabrafenib can harm an unborn baby. Both men and women must use effective contraception during treatment and for at least 2 weeks after the final dose.
• Are planning any surgery — dabrafenib should typically be held before surgical procedures as it may impair wound healing. Discuss timing with your surgeon and oncologist.
• Have liver or kidney problems — dosage adjustments may be needed

Drug interactions: Dabrafenib can interact with many common medicines including certain antibiotics, antifungals, anticoagulants, and heartburn medications. Always give your full medication list to your oncologist and pharmacist before starting.

Generic Dabrafenib vs Brand Name Tafinlar — What’s the Difference?

The active pharmaceutical ingredient is identical: dabrafenib mesylate. Generic manufacturers must demonstrate bioequivalence — meaning the medicine is absorbed into the bloodstream in the same way and at the same rate as the brand version.

The key differences are:

The cost of branded Tafinlar can reach $15,000–$20,000 per month in the United States. Our generic dabrafenib gives patients access to the same treatment at a price that doesn’t force anyone to choose between medicine and everything else in their life.

Dabrafenib Price — Why Choose 100Meds?

We understand that a cancer diagnosis already puts enormous pressure on patients and families — financially and emotionally. Our mission at 100Meds has always been to remove the cost barrier to life-saving cancer medicine.

• ✔ Competitive international pricing — we offer generic dabrafenib at a fraction of US/UK market prices
• ✔ Worldwide shipping — DHL Express, EMS, and other trusted couriers to USA, UK, Canada, Australia, India, and more
• ✔ Delivery in 2–15 days depending on your location
• ✔ Licensed generic manufacturers — all products are sourced from WHO-GMP certified facilities
• ✔ Real human support — our team is available via live chat and WhatsApp to help with your order and answer questions

Frequently Asked Questions

Is a prescription required to order dabrafenib from 100Meds?

Yes. Dabrafenib is a prescription cancer medicine. We require a valid prescription from a licensed oncologist before processing your order. This is for your safety.

Does my cancer need to be tested for BRAF mutation before starting dabrafenib?

Yes, absolutely. Dabrafenib only works in BRAF V600-mutated cancers. Your oncologist will order a molecular test on your tumor tissue or blood before prescribing this medicine. Taking dabrafenib without confirmed BRAF mutation status is not appropriate.

Can I take dabrafenib if I have NSCLC (lung cancer)?

Yes — in combination with trametinib, dabrafenib is FDA-approved for metastatic NSCLC with BRAF V600E mutation. Ask your oncologist whether this combination is appropriate for your specific case.

What if I experience fever while on dabrafenib?

Fever is one of the most common side effects of dabrafenib, particularly in the first few months. If your temperature exceeds 38°C (100.4°F), contact your oncologist promptly. They may advise a temporary dose hold and supportive medication. Do not self-manage persistent fever without medical advice.

How should I store dabrafenib capsules?

Store at room temperature (below 30°C / 86°F), in the original packaging, away from moisture and direct sunlight. Keep out of reach of children.

Can dabrafenib be taken with food?

No — dabrafenib must be taken on an empty stomach, at least 1 hour before eating or 2 hours after a meal. Food significantly reduces absorption of the drug.

Is dabrafenib used in children?

Dabrafenib has an approved pediatric formulation (dispersible tablets) for certain indications in children. However, adult capsules are prescribed for adults only. Discuss pediatric use with your child’s oncologist.

Related Products You May Also Need

Dabrafenib is frequently prescribed in combination with trametinib. If your oncologist has prescribed the combination regimen, you may also be interested in:

• Generic Trametinib Tablets — MEK inhibitor, commonly combined with dabrafenib
• View All Melanoma Medicines →
• View All Cancer Medicines →

Also see our Ivosidenib product page for patients with IDH1-mutated AML.

Medical References & Further Reading

For patients and healthcare providers who want to read the clinical evidence behind dabrafenib:

• FDA Prescribing Information for Dabrafenib (Tafinlar) — U.S. Food & Drug Administration
• Five-Year Outcomes with Dabrafenib + Trametinib — NEJM — Robert et al., New England Journal of Medicine
• Dabrafenib and Trametinib in Treating Melanoma — Clinical Cancer Research — AACR Journals
• FDA-Approved Melanoma Treatments — AIM at Melanoma Foundation

Last reviewed by the 100Meds medical content team. This page is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist for diagnosis, treatment decisions, and medication management.